Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) EPS (Basic) (2016 - 2026)

Sunshine Biopharma filings provide 14 years of EPS (Basic) readings, the most recent being -$0.46 for Q4 2025.

  • On a quarterly basis, EPS (Basic) fell 107.31% to -$0.46 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.48, a 77.54% increase, with the full-year FY2025 number at -$1.44, up 80.33% from a year prior.
  • EPS (Basic) hit -$0.46 in Q4 2025 for Sunshine Biopharma, down from -$0.19 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $6.29 in Q4 2024 to a low of -$85.65 in Q4 2023.
  • Median EPS (Basic) over the past 5 years was -$1.08 (2021), compared with a mean of -$11.49.
  • Biggest five-year swings in EPS (Basic): skyrocketed 135.66% in 2021 and later plummeted 237133.33% in 2023.
  • Sunshine Biopharma's EPS (Basic) stood at $0.97 in 2021, then plummeted by 259.67% to -$1.55 in 2022, then tumbled by 5430.04% to -$85.65 in 2023, then soared by 107.34% to $6.29 in 2024, then crashed by 107.31% to -$0.46 in 2025.
  • The last three reported values for EPS (Basic) were -$0.46 (Q4 2025), -$0.19 (Q3 2025), and -$0.39 (Q2 2025) per Business Quant data.